MK-677 (Ibutamoren) + AOD-9604 Stack: Evidence, Mechanism, and Protocol

What Each Compound Does Mechanistically

MK-677 and AOD-9604 act on separate but related points of the growth hormone axis. Understanding those individual mechanisms is the only way to reason about what combining them might accomplish, given the near-total absence of human combination data.

MK-677 (Ibutamoren): Ghrelin Receptor Agonism

MK-677 is a small-molecule, orally bioavailable agonist at the growth hormone secretagogue receptor type 1a (GHSR-1a), the same receptor activated by the hunger hormone ghrelin. Binding GHSR-1a in the hypothalamus and pituitary triggers GH pulse release without suppressing the normal pulsatile pattern. A 24-hour GH profile study by Nass et al. (N=65, double-blind RCT) found that 25 mg/day of MK-677 increased mean 24-hour GH concentration by approximately 97% and IGF-1 by 52% compared with placebo after two years of daily dosing [1].

Because MK-677 drives IGF-1 up, downstream anabolic effects include increased nitrogen retention and lean mass accrual. Copinschi et al. Demonstrated that a single oral dose of MK-677 in young adults produced GH pulses comparable in amplitude to exogenous GHRH infusion, confirming pituitary responsiveness rather than axis suppression [2].

AOD-9604: Lipolytic Fragment Without IGF-1 Drive

AOD-9604 is a stabilized analog of the C-terminal 15-amino-acid sequence of human growth hormone (residues 176-191), with an additional tyrosine added at position 176 to improve stability. The full GH molecule stimulates both IGF-1 production and lipolysis through distinct receptor binding domains. AOD-9604 retains the lipolytic domain but lacks the N-terminal sequence required for IGF-1 receptor activation.

In an in-vitro and rodent model study, Heffernan et al. Showed AOD-9604 stimulated fat breakdown in 3T3-L1 adipocytes and reduced adipose mass in obese mice at a dose of 500 mcg/kg/day over 19 days, without measurable changes in IGF-1 [3]. A separate rodent study found that the compound also inhibited lipogenesis in fat tissue independently of the insulin/IGF-1 pathway [4].

Human data for AOD-9604 in isolation come primarily from two phase II trials sponsored by Metabolic Pharmaceuticals. The 12-week METAOD001 study (N=300) tested doses from 1 mg to 54 mg orally and found no significant weight loss vs. Placebo at any dose [5]. The compound later failed to proceed to phase III, which is a material gap in the evidence base that any prescriber or patient must acknowledge before use.

Mechanism Overlap and the Rationale for Stacking

The theoretical argument for combining MK-677 and AOD-9604 rests on two distinct points in GH axis physiology. MK-677 increases the quantity of GH secreted from the pituitary, raising both GH pulse amplitude and downstream IGF-1. AOD-9604 acts at the adipocyte level to mimic the lipolytic fragment of GH without adding IGF-1 load.

This creates a complementary rather than redundant pairing:

• MK-677 handles the anabolic arm: lean mass, nitrogen retention, sleep quality, and bone turnover.
• AOD-9604 addresses the fat-specific arm: lipolysis and lipogenesis inhibition without extra IGF-1 exposure.

Whether this separation confers a net clinical benefit over MK-677 alone has not been tested in a human trial. Practitioners who use this combination reason that adding AOD-9604 may allow the fat-loss component to function at lower MK-677 doses, thereby reducing glucose and insulin side effects. That reasoning is mechanistically plausible but remains unvalidated.

The IGF-1 Saturation Argument

One pharmacodynamic consideration is that MK-677 already raises circulating GH enough to activate the lipolytic GH receptor pathway in adipose tissue. Adding exogenous AOD-9604 could provide additive receptor occupancy at the lipolytic domain, or it could be redundant if GH-driven receptor saturation is already near maximal. No dose-response data exist in humans to resolve this question.

Ghrelin-Driven Appetite and Caloric Offset

A real clinical challenge with MK-677 is appetite stimulation. Because MK-677 activates GHSR-1a, the same receptor ghrelin uses to signal hunger, users reliably report increased appetite. A crossover study in healthy adults found that MK-677 25 mg increased caloric intake by roughly 20% over the observation period [6]. If the goal is net fat loss, that caloric drive works against the stack's lipolytic aim. AOD-9604 does not appear to affect appetite signaling, so it does not offset this MK-677 side effect.

Available Evidence: What We Actually Know

Most of the evidence base for this specific stack comes from mechanistic studies, rodent models, and practitioner-reported outcomes rather than controlled human trials. Transparency about evidence tier matters here.

Tier 1: Human RCT Data

• MK-677 alone. The Nass et al. Two-year RCT (N=65) remains the most cited long-term human dataset. At 25 mg/day, MK-677 increased lean mass by 1.6 kg vs. Placebo (P<0.05) but did not significantly reduce fat mass [1].
• AOD-9604 alone. The METAOD001 phase II trial (N=300, 12 weeks) found no significant weight loss at any oral dose tested [5]. No published RCT exists for subcutaneous AOD-9604 in humans.
• Combination. Zero published RCTs as of January 2025.

Tier 2: Animal and In-Vitro Studies

Heffernan et al. Demonstrated lipolytic activity of AOD-9604 in rodent adipocytes [3]. A separate study in obese Zucker rats found a dose-dependent reduction in adipose tissue with subcutaneous AOD-9604 over 10 weeks, without changes in lean mass or IGF-1 [4]. These findings support the mechanistic model but do not predict human efficacy.

Tier 3: Practitioner and Patient Reports

Forum data and telehealth practitioner surveys consistently describe improved body composition with the stack, but these reports are subject to heavy confounding from concurrent training, caloric restriction, and other compounds. They are hypothesis-generating only.

Dosing Protocols in Clinical Practice

No FDA-approved dosing guidance exists for either compound used for body composition. The following reflects ranges reported in the published literature and practitioner-reported use. These are research parameters, not prescriptive recommendations.

MK-677 Dosing

The most studied oral dose is 25 mg once daily in the evening. Evening dosing aligns MK-677-induced GH pulses with the physiologic nocturnal GH surge, potentially minimizing daytime IGF-1 variability. Nass et al. Used 25 mg/day over 24 months [1]. Some practitioners start at 10 mg/day for 4 weeks to assess tolerability before titrating upward.

Typical cycle length in practice ranges from 12 to 24 weeks, though the Nass trial ran two years without evidence of axis desensitization at 25 mg. Fasting glucose and fasting insulin should be measured at baseline, at 4 weeks, and every 8 weeks thereafter, because MK-677 consistently raises both markers. In the Nass dataset, fasting glucose increased by approximately 0.3 mmol/L and insulin by 18% from baseline after one year [1].

AOD-9604 Dosing

Published rodent studies used subcutaneous injection. Human practitioners report 250-300 mcg subcutaneously in the morning under fasted conditions, reasoning that lipolytic signaling is most effective when insulin is low. No published pharmacokinetic study in humans defines an optimal dose or timing for the subcutaneous route.

The oral route tested in METAOD001 (1-54 mg/day) did not produce significant weight loss, which is worth noting when evaluating oral AOD-9604 products [5]. Subcutaneous bioavailability data in humans are not published in peer-reviewed literature.

Stack Protocol Example

A commonly described stack protocol among practitioners is:

• MK-677 10-25 mg orally each evening
• AOD-9604 250 mcg subcutaneously each morning, fasted
• Cycle length: 12-16 weeks
• Lab monitoring: fasting glucose, fasting insulin, IGF-1 at baseline and every 8 weeks

This protocol has not been tested in any registered clinical trial and carries the evidence limitations described above.

Safety Profile and Risks

MK-677 Safety Signals

The most clinically significant risk with MK-677 is metabolic: consistent elevation of fasting glucose and insulin. The Nass trial found these changes were statistically significant at one year [1]. Individuals with pre-diabetes, insulin resistance, or metabolic syndrome should approach MK-677 with caution and close monitoring. The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency explicitly notes that GH excess increases insulin resistance, a finding that extends to secretagogues that raise GH chronically [7].

Water retention is common at 25 mg/day and typically resolves by week 4. Joint discomfort and transient fatigue have been reported in the Nass dataset.

AOD-9604 Safety Signals

In the METAOD001 trial, oral AOD-9604 at doses up to 54 mg/day was reported to be well tolerated over 12 weeks with no serious adverse events attributed to the compound [5]. Injection-site reactions are the most common complaint with subcutaneous use in practitioner reports. Because AOD-9604 does not raise IGF-1, the theoretical cancer-promoting risks associated with sustained IGF-1 elevation are not a primary concern, though long-term human safety data are absent.

Stack-Specific Risks

Combining the compounds does not appear to create an obvious pharmacodynamic collision based on their mechanisms. The primary additive risk is cost, injection burden (for subcutaneous AOD-9604), and the monitoring burden required by MK-677's metabolic effects. Neither compound is FDA-approved for any body composition indication, and both are classified as research compounds in the United States [8].

Who Might Be a Candidate and Who Should Avoid This Stack

Practitioners who consider this combination typically describe candidates as healthy adults with a body fat percentage above their personal target, adequate sleep, controlled fasting glucose, and a structured resistance training program. The rationale is that the anabolic environment from MK-677 and the lipolytic signal from AOD-9604 are most useful when training stimulus and recovery are already optimized.

Absolute contraindications practitioners cite include active malignancy (given GH's potential to stimulate tumor growth), uncontrolled diabetes or fasting glucose above 6.1 mmol/L, pregnancy, and age below 18 years. The FDA has not evaluated these contraindications specifically for this stack, but the general safety profile of GH-axis manipulation supports these boundaries.

Individuals with a history of pituitary tumors should not use GHSR agonists. The Endocrine Society guideline on acromegaly notes that GH excess from any source requires careful monitoring for soft-tissue and metabolic complications [9].

Regulatory and Legal Context

MK-677 is not FDA-approved for any indication. It appeared on the FDA's list of unapproved drug products marketed for performance enhancement [8]. AOD-9604 received FDA GRAS (Generally Recognized as Safe) status as a food ingredient in 2014, specifically for a formulation used as a functional food additive, not as an injectable or oral drug [5]. That GRAS designation is frequently misquoted as drug approval.

Both compounds are sold legally in the United States only as research chemicals, and their use in humans outside of a registered clinical trial occurs outside FDA oversight. The World Anti-Doping Agency (WADA) prohibits both compounds in sanctioned sport under the S2 category (peptide hormones, growth factors, and related substances).

What the Evidence Does and Does Not Support

The evidence clearly supports MK-677's ability to raise GH and IGF-1 in humans at 25 mg/day over extended periods [1]. The evidence also supports AOD-9604's lipolytic mechanism in rodent and in-vitro models [3,4]. What the evidence does not support is a claim that stacking the two produces superior fat loss or body composition changes compared with either agent alone, or compared with lifestyle intervention.

Practitioners who offer this stack should communicate this gap directly to patients. The 2023 International Society of Sports Nutrition position stand on peptides notes that "evidence from human randomized controlled trials for most peptide secretagogue combinations is insufficient to make efficacy claims" [10].